Incontinence affects approximately 18% of the population, with significant variation across care settings. Among incontinent patients, the prevalence of incontinence-associated dermatitis (IAD) ranges from 8.4% in long-term care facilities to 19% in acute care settings, highlighting its widespread nature. Notably, nearly 1 in 5 incontinent patients experience IAD, while its prevalence in the general patient population is estimated at 4.3%.
This condition, characterized by the involuntary loss of urine or feces, poses significant physical and emotional challenges. While often perceived as merely a bladder or bowel issue, incontinence profoundly impacts skin health. Prolonged exposure to moisture, urine, and feces can lead to complications such as IAD, infections, and pressure ulcers, particularly in older or immobile individuals. Fecal incontinence, in particular, raises the risk, with IAD prevalence reaching 26% among patients using fecal management systems compared to 12% in those with urinary incontinence alone.
Maintaining skin integrity is critical for individuals managing incontinence, as healthy skin serves as a vital barrier against irritants and pathogens. Effective skincare solutions, including barrier creams, protective ointments, and advanced absorbent products, are essential in minimizing damage. Calmoseptine, a well-known barrier ointment, stands out for its ability to soothe, protect, and promote healing in irritated skin.
This article delves into the intersection of incontinence and skin health, focusing on the role of products like Calmoseptine and innovations in absorbent wraps and pads. By understanding these solutions, patients and caregivers can adopt comprehensive strategies to guard against skin complications, enhancing comfort and quality of life.
Incontinence-associated dermatitis (IAD) is a common and distressing condition caused by prolonged exposure of the skin to urine or feces. This condition is prevalent in nursing homes and among individuals receiving long-term care, with rates ranging from 5.6% to 50%, especially in those with fecal incontinence. IAD often goes undiagnosed, as many individuals self-manage or lack access to proper care, highlighting the critical need for awareness and intervention.
The typical presentation of IAD includes inflammation, redness, swelling, and, in severe cases, blister formation. It commonly affects sensitive areas such as the female labial region, male scrotum, and the thighs and buttocks in both sexes. The risk significantly increases when urinary and fecal incontinence co-occur. Fecal matter poses a greater threat than urine, as it contains digestive enzymes and bacteria that elevate skin pH, leading to epidermal damage .
IAD is exacerbated by several factors, including friction from absorbent materials, frequent washing with soap and water, and overhydration of the skin. Poorly managed care, such as inadequate cleaning or prolonged exposure to irritants, further aggravates the condition. The use of abrasive washcloths or thick ointments can also weaken the skin barrier, increasing susceptibility to irritation and breakdown.
For immobile individuals, the physical stress of friction and shearing compounds the effects of chemical irritants, leading to weakened skin and an increased risk of pressure injuries. Addressing IAD requires comprehensive strategies that include proper hygiene, gentle cleaning methods, and the use of protective products like barrier creams and absorbent pads to reduce exposure and friction while preserving skin integrity.
Calmoseptine® Ointment is a versatile skin barrier product designed to protect and soothe irritated skin, particularly in individuals with incontinence. Its key ingredients include zinc oxide, which acts as a barrier to moisture and irritants, and menthol, which provides a cooling effect that alleviates itching and discomfort. These components work synergistically to reduce inflammation, protect against further damage, and promote skin healing.
Clinical studies have demonstrated the efficacy of Calmoseptine in managing incontinence-associated dermatitis (IAD). In a randomized study involving patients with urinary and/or fecal incontinence, Calmoseptine was significantly more effective than Desitin Maximum Strength Diaper Rash Paste. By day six, 25% of patients treated with Calmoseptine were completely healed, compared to only 7.7% in the Desitin group (p=0.009). Additionally, Calmoseptine led to smaller affected areas and greater reductions in IAD severity from the first day of use onward. These results were consistent even after accounting for confounding factors such as steroid use, which can impair wound healing.
For optimal results, Calmoseptine should be applied as part of a structured skincare routine. Clean the affected area gently with a non-abrasive cloth and pH-balanced cleanser. Avoid excessive scrubbing or the use of harsh soaps, which can damage the skin further. After drying the area thoroughly, apply a thin layer of Calmoseptine to protect the skin from moisture and irritants. Regular reapplication is recommended, especially after episodes of incontinence, to maintain skin integrity.
By incorporating Calmoseptine into daily care routines, patients and caregivers can effectively manage IAD, reduce discomfort, and support the healing process. This product is a valuable tool in preventing complications and ensuring the overall well-being of individuals with incontinence.
Advancements in incontinence skin care have revolutionized how skin health is managed in patients at risk of incontinence-associated dermatitis (IAD). Key innovations include the development of modern barrier creams, pH-balanced cleansers, and moisturizers that protect and restore skin integrity.
Structured Skin Care Routines
Evidence emphasizes the importance of structured routines involving cleansing, moisturizing, and protecting the skin. Using products like pH-balanced cleansers and moisturizers with emollients helps maintain the skin's acid mantle and hydration levels, reducing the risk of IAD. Effective barrier products create a semi-permeable shield against irritants in urine and feces, though proper selection is vital to prevent interference with absorbent pad efficacy.
Innovative Products
Recent advancements include breathable materials for pads and film-forming skin protectants like Cavilon No Sting Barrier Film. These products reduce the frequency of application while maintaining skin protection, offering cost-effective solutions without compromising care. Studies suggest products such as Calmoseptine, with optimized zinc oxide concentrations, provide enhanced protection and healing compared to traditional formulations .
Technological Integration
The incorporation of technology in product design has led to materials that adapt to skin pH and improve breathability. Innovations like perineal washcloths with integrated cleansing, moisturizing, and protective properties simplify routines, reducing caregiver workload while improving patient outcomes
Educational Impact
Carer education on optimal skin care practices and product usage plays a critical role. Structured protocols have reduced IAD incidence from 25% to less than 5% in some settings , highlighting the importance of informed care.
Incorporating these innovations and evidence-based practices ensures better outcomes for patients, improving both physical and emotional well-being.
Choosing high-quality absorbent products is crucial for effective incontinence care and skin protection. These products act as the first line of defense against moisture-related issues, working alongside protective ointments like Calmoseptine to minimize skin irritation, prevent rashes, and reduce the risk of pressure ulcers.
For both caregivers and patients, absorbent wraps and pads offer significant advantages. They simplify hygiene routines, allowing for quick changes in under 60 seconds, while their no-lift design reduces physical strain for caregivers. This ensures a smoother and more comfortable care process.
For men who are bed-bound or use wheelchairs, these products provide an innovative solution for urine management, tailored to their unique needs. Whether used during the day or for nighttime care, absorbent wraps help maintain skin health, enhance comfort, and improve overall quality of life for those managing incontinence.
For active men, absorbent wraps are particularly effective for nighttime use, minimizing sleep interruptions by securely collecting urine before it contacts the skin. By doing so, they not only promote better rest but also drastically lower the risk of skin irritation and rashes. QuickChange Wraps excel at protecting skin integrity, actively reducing exposure to irritants and creating a healthier environment for sensitive areas.
Moreover, these products prioritize patient dignity and quality of life. Their discreet and efficient design helps patients maintain comfort and confidence while enabling caregivers to provide care efficiently and compassionately. By combining absorbent wraps with complementary products like Calmoseptine, users and caregivers can effectively manage incontinence while promoting overall skin health.
Preserving skin health in individuals managing incontinence requires a holistic approach that combines advanced products with personalized care strategies. Topical protectants like Calmoseptine are pivotal in creating a robust barrier against irritants, reducing the risk of incontinence-associated dermatitis (IAD) and other skin complications. Complementing these, innovative solutions such as QuickChange Wrap offer streamlined care, minimizing disruptions while protecting sensitive skin.
QuickChange Wrap goes beyond convenience, transforming caregiving by reducing strain and fostering patient dignity and comfort. This innovative product not only simplifies routines but also helps establish a healthier and more supportive environment for both patients and caregivers.
For those seeking a more effective way to manage incontinence, exploring advanced solutions like QuickChange Wrap can make a meaningful difference in comfort, care, and quality of life. Experience the benefits and see the transformation for yourself.
For individuals: Purchase a 10 Count Trial Pack here.
For healthcare institutions: Request a professional use sample pack here.
Take the step toward improved quality of life for those you care for.
Bardsley, A. (2013). Prevention and management of incontinence-associated dermatitis. Nursing Standard, 27(44), 41–46. https://doi.org/10.7748/ns2013.07.27.44.41.e7618
PMID: 23940938.
Beeckman, D., Van Damme, N., Schoonhoven, L., Van Lancker, A., Kottner, J., Beele, H., Gray, M., Woodward, S., Fader, M., Van den Bussche, K., Van Hecke, A., De Meyer, D., & Verhaeghe, S. (2016). Interventions for preventing and treating incontinence-associated dermatitis in adults. Cochrane Database of Systematic Reviews, 11(11), CD011627. https://doi.org/10.1002/14651858.CD011627.pub2
PMID: 27841440; PMCID: PMC6464993.
Buckley, B., Dofitas, R., Baltazar, W., Quiambao, P., & Razor, B. (n.d.). Topical zinc oxide-based creams in a structured care regimen for the treatment of incontinence-associated dermatitis in hospitalized adults and older children: A randomized, controlled trial. International Continence Society. https://www.ics.org/Abstracts/Publish/218/000321.pdf
DailyMed. (n.d.). CALMOSEPTINE- zinc oxide and menthol ointment. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9aa48789-dc1c-452e-8125-f0cd0c792d5b
Kayser, S. A., Phipps, L., VanGilder, C. A., & Lachenbruch, C. (2019). Examining prevalence and risk factors of incontinence-associated dermatitis using the international pressure ulcer prevalence survey. Journal of Wound Ostomy and Continence Nursing, 46(4), 285–290. https://doi.org/10.1097/won.0000000000000548
Published Incontinence-Associated Dermatitis Clinical Study. (n.d.). Calmoseptine Ointment. https://calmoseptineointment.com/published
QuickChange Men's Incontinence Wrap. (n.d.). QuickChange Men’s Maximum Absorbency Incontinence Wrap by UI Medical. QuickChange Men’s Incontinence Wrap. https://quickchange.com/?srsltid=AfmBOoqSJWrmPw73RYUa2Xj-dnJ71UZ3XCz0AQfEY9eew_-9yMAZNmZX
Ramirez Razor, R. B. C., Quiambao, R. B., Buckley, P. Mhs. B., Dofitas, M. Ms., & Baltazar, M. (2014). Incontinence-associated dermatitis (IAD) study: Blinded assessment and treatment with zinc oxide-based ointment. WCET Journal, 34(4). https://www.calmoseptineointment.com/public/IDA%20Study%20PDF.pdf
Silver, N. (2017, April 7). What is incontinence-associated dermatitis and how is it treated? Healthline. https://www.healthline.com/health/overactive-bladder/incontinence-associated-dermatitis#causes
Urology & Continence Care Today. (n.d.). Moisture-associated skin damage caused by incontinence. UCC Today. https://www.ucc-today.com/journals/issue/launch-edition/article/moisture-associated-skin-damage-incontinence
Williams, C. (1998). 3M Cavilon No Sting Barrier Film in the protection of vulnerable skin. British Journal of Nursing, 7(10), 613–615. https://doi.org/10.12968/bjon.1998.7.10.5688 PMID: 9775773.